News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
News Datroway filed for TNBC in EU after data delay Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News ASH: Gilead preps filing for anito-cel on iMMagine-1 data Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.
News ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.
News Gilead, Amgen kick off facility investments in US This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
